Prostaglandins Leukotrienes and Essential Fatty Acids

Prostaglandins Leukotrienes and Essential Fatty Acids is an Elsevier journal founded in 1988, when it took over the volume sequence of Prostaglandins, Leukotrienes and Medicine. It reports on lipids in cellular, organ and whole organism function, gives human studies particular weight, and recorded a 2025 Journal Impact Factor of 2.4.《前列腺素、白三烯与必需脂肪酸》是 Elsevier 旗下的期刊，1988 年创刊并接续《前列腺素、白三烯与医学》的卷序。刊物研究脂质在细胞、器官与整体功能中的作用，对人体研究给予特别权重，2025 年影响因子为 2.4。

Scope

• The scope statement covers every aspect of the roles lipids play in cellular, organ and whole organism function, and states plainly that human studies receive particular emphasis.范围声明覆盖脂质在细胞、器官与整体机体功能中作用的各个方面，并明言人体研究受到特别侧重。

• Reach extends across all medical specialties rather than a single clinical domain, so cardiology, oncology, neurology and internal medicine sit inside the same remit.覆盖范围横跨所有医学专科，并不局限于某一临床领域，心脏病学、肿瘤学、神经病学与内科学因此同在这份刊物之内。

• The statement links the subject to therapeutics, describing work in this field as closely relevant to the development of new treatments for disease.声明把这一学科与治疗学相连，称本领域的研究与疾病新疗法的开发关系密切。

• Prostaglandins lead the three families named in the title, taking in their synthesis from arachidonic acid, the cyclooxygenase enzymes behind it, the receptors they act on and their effects on smooth muscle, platelets and blood vessels.前列腺素列于刊名三族之首，内容含其由花生四烯酸合成的路径、起催化作用的环氧化酶、所作用的受体，以及对平滑肌、血小板与血管的影响。

• Leukotrienes bring the lipoxygenase route into view, with cysteinyl leukotrienes in asthma and allergic inflammation and the receptor antagonists that followed from that work.白三烯把脂氧合酶途径带入视野，涵盖半胱氨酰白三烯在哮喘与过敏性炎症中的作用，以及由此发展出的受体拮抗剂。

• Essential fatty acids cover linoleic and alpha-linolenic acid, their long-chain products arachidonic acid, eicosapentaenoic acid and docosahexaenoic acid, and the balance between omega-6 and omega-3 supply.必需脂肪酸涵盖亚油酸与 α-亚麻酸，其长链产物花生四烯酸、二十碳五烯酸与二十二碳六烯酸，以及 ω-6 与 ω-3 供给之间的平衡。

• Eicosanoid signalling holds the middle ground, and the resolution of inflammation has become a steady theme, with lipoxins, resolvins, protectins and maresins treated as products of the same fatty acid pool.类花生酸信号占据中间地带，炎症消退已成常设主题，脂氧素、消退素、保护素与 Maresin 都视作同一脂肪酸池的产物。

• Analytical papers are admitted as well, running from the gas chromatography and mass spectrometry of fatty acids to lipidomic profiling of plasma, erythrocytes and tissue.分析类论文同样在列，从脂肪酸的气相色谱与质谱测定，到血浆、红细胞与组织的脂质组学谱图。

• Dietary studies appear regularly, since intake of fish, vegetable oils and dairy fat sets the fatty acid composition of membranes and the substrate supply for eicosanoid synthesis.膳食研究时常出现，鱼类、植物油与乳脂的摄入量决定膜脂肪酸组成，也决定类花生酸合成所能得到的底物。

• The brain is a recurring subject, from docosahexaenoic acid in membrane phospholipids to lipid signalling in neuroinflammation and the interplay of ketones and lipids in ageing.脑是反复出现的题材，从膜磷脂中的二十二碳六烯酸，到神经炎症中的脂质信号，以及衰老过程中酮体与脂质的相互作用。

• Inflammation and immunity run through much of the content, where eicosanoids and omega-3 derived mediators act on neutrophils, macrophages and the endothelial lining.炎症与免疫贯穿刊物的多数内容，类花生酸与 ω-3 衍生介质作用于中性粒细胞、巨噬细胞与血管内皮。

• Cardiovascular and metabolic papers deal with platelet function, vascular tone, insulin sensitivity and the plasma lipid profile, with controlled feeding trials a familiar design.心血管与代谢类论文处理血小板功能、血管张力、胰岛素敏感性与血脂谱，受控膳食试验是常见设计。

• Cancer, bone and reproduction also appear, since prostaglandins act on tumour stroma, on osteoclast and osteoblast activity, and on the uterine and ovarian cycle.肿瘤、骨骼与生殖同样在列，前列腺素作用于肿瘤间质、破骨与成骨细胞活动，以及子宫与卵巢周期。

• Clinical material is welcome beside laboratory work, a bias that follows from the emphasis on human studies written into the aims.临床材料与实验室工作并收，这一偏向源自宗旨中对人体研究的侧重。

History

• Volume 31, number 1 appeared in January 1988 as the first issue under the present title, and the medical index takes its coverage from that number.第 31 卷第 1 期于 1988 年 1 月出版，是现刊名下的首期，医学书目索引亦自该期起收录。

• Numbering continued rather than restarted, because Prostaglandins, Leukotrienes and Medicine had closed at volume 30 in 1987.卷号续接而未重新起算，前身刊《前列腺素、白三烯与医学》已于 1987 年止于第 30 卷。

• Churchill Livingstone of Edinburgh and New York is the imprint recorded for the launch year, and the title now sits in the Elsevier catalogue on ScienceDirect.创刊年登记的出版方为爱丁堡与纽约的 Churchill Livingstone，该刊现列于 ScienceDirect 上的 Elsevier 目录。

• An older arrangement noted in the bibliographic record made one issue per volume appear in two continuously paged parts, the second of them called Reviews.书目记录还留有旧日排法，每卷的一期分作两个连续编页的部分，第二部分题为 Reviews。

• Monthly publication is the rhythm the medical index records, and twelve issues a year stand beside an annual count of four volumes.医学书目所记刊期为按月出版，每年 12 期与一年四卷并行。

• The 2024 volumes ran from 200 to 203 and the 2025 volumes from 204 to 207, three numbers to each volume.2024 年的卷次为第 200 至 203 卷，2025 年为第 204 至 207 卷，每卷三期。

• Volumes 208 to 211 carry the 2026 output, so the four-volume year is now the settled pattern.2026 年的内容由第 208 至 211 卷承载，一年四卷已成定式。

• Impact factor readings have stayed inside a narrow band, 3.015 for 2022, 2.9 for 2023, 3.2 for 2024 and 2.4 for 2025, with a five-year value of 2.8.影响因子长期在窄区间内摆动，2022 年 3.015，2023 年 2.9，2024 年 3.2，2025 年 2.4，五年值为 2.8。

• In the 2025 category tables the title stands 244th of 328 in biochemistry and molecular biology, 161st of 207 in cell biology and 135th of 198 in endocrinology and metabolism.2025 年类目表把该刊排在生物化学与分子生物学 328 刊中的第 244 位，细胞生物学 207 刊中的第 161 位，内分泌学与代谢 198 刊中的第 135 位。

• The same release counts 32 articles and 3944 citations for the year, a journal citation indicator of 0.54, a percentile of 32.1 and a cited half-life of 11.8 years.同一榜单计该年论文 32 篇、被引 3944 次，期刊引用指标 0.54，百分位 32.1，被引半衰期 11.8 年。

• Access is subscription based with a hybrid route for authors, and gold open access articles accounted for 31.25 per cent of the output in the 2025 reporting year.刊物以订阅制为基础，为作者保留混合式开放途径，2025 报告年的金色开放获取文章占产出的 31.25%。

• Abstracting rests on Science Citation Index Expanded along with MEDLINE, PubMed and Index Medicus.文摘收录依托 Science Citation Index Expanded 与 MEDLINE、PubMed、Index Medicus。

• Two serial numbers identify the title, 0952-3278 for the printed edition and 1532-2823 for the electronic one.该刊有两个刊号，印刷版为 0952-3278，电子版为 1532-2823。

Editors

• Richard P. Bazinet of the University of Toronto in Canada holds the editor-in-chief position at the head of the board.编委会由多伦多大学的 Richard P. Bazinet 领衔，出任主编。

• Two associate editors sit beside him, Chuck T. Chen of the University of Toronto Temerty Faculty of Medicine and Francesco Visioli of the University of Padua.两位副编辑与主编共事，一位是多伦多大学 Temerty 医学院的 Chuck T. Chen，另一位是帕多瓦大学的 Francesco Visioli。

• Chen works on lipid metabolism, nutrition, the brain and alcohol, a combination that reaches most of the territory the journal covers.Chen 的研究方向为脂质代谢、营养、脑与酒精，覆盖面触及刊物的大部分领域。

• Visioli, in the Department of Molecular Medicine at Padua, works on micronutrients, functional foods and nutraceuticals, which is the applied end of the same field.Visioli 任职于帕多瓦大学分子医学系，研究微量营养素、功能食品与营养补充剂，属于这一领域的应用一端。

• D. F. Horrobin is named as founding editor and M. Manku as editor emeritus, two titles the board page keeps alongside the current list.编委页面在现任名单之外保留两个称谓，创刊主编为 D. F. Horrobin，荣休编辑为 M. Manku。

• The board counts 27 members from 12 countries and territories, the United States holding six seats, Canada five and Italy four.编委会共 27 人，来自 12 个国家与地区，美国占 6 席，加拿大 5 席，意大利 4 席。

• Britain, Sweden, France, the Netherlands, Norway, Japan, Australia and New Zealand fill the remaining seats, which puts four continents on the list.英国、瑞典、法国、荷兰、挪威、日本、澳大利亚与新西兰分占其余席位，名单因此覆盖四大洲。

• Philip C. Calder of Southampton brings omega-3 fatty acids and immune function, and Robert S. Chapkin of Texas A&M works on lipid second messengers.南安普顿大学的 Philip C. Calder 带来 ω-3 脂肪酸与免疫功能方面的专长，得克萨斯 A&M 大学的 Robert S. Chapkin 研究脂质第二信使。

• Stephen Cunnane of Toronto studies brain lipids and ketone bodies, while V. Di Marzo of the CNR institute in Pozzuoli is known for endocannabinoid research.多伦多大学的 Stephen Cunnane 研究脑脂质与酮体，波佐利 CNR 研究所的 V. Di Marzo 以内源性大麻素研究著称。

• Jesper Haeggstrom and Jan Palmblad, both at the Karolinska Institute in Stockholm, keep leukotriene and eicosanoid work represented on the board.斯德哥尔摩卡罗林斯卡学院的 Jesper Haeggstrom 与 Jan Palmblad 让白三烯与类花生酸研究在编委会中占有一席。

• Harvey Herschman of UCLA, Song Hong of LSU Health New Orleans and Y. Urade of Tsukuba carry prostaglandin and lipid mediator research from three countries.加州大学洛杉矶分校的 Harvey Herschman、路易斯安那州立大学新奥尔良健康科学中心的 Song Hong 与筑波大学的 Y. Urade 从三个国家带来前列腺素与脂质介质研究。

• Asim Duttaroy in Oslo, Michel Lagarde at INSA Lyon and Marc Pouliot at Laval extend the board into nutrition, membrane lipids and leukocyte biology.奥斯陆的 Asim Duttaroy、里昂国立应用科学学院（INSA Lyon）的 Michel Lagarde 与拉瓦尔大学的 Marc Pouliot 把编委的视野扩展到营养、膜脂与白细胞生物学。

• Ken D. Stark at Waterloo works on lipidomics, Marlena Kruger at Massey on bone metabolism and Frits A. J. Muskiet in Groningen on fatty acid status.滑铁卢大学的 Ken D. Stark 研究脂质组学，梅西大学的 Marlena Kruger 研究骨代谢，格罗宁根的 Frits A. J. Muskiet 研究脂肪酸营养状况。

• Other seats belong to Ikuo Morita of the Institute of Science Tokyo, E. H. Oliw of Uppsala and Andrew Sinclair of Deakin, with Carlo Agostoni in Milan and Nan Chiang at Brigham and Women's among the remaining members.其余席位中，东京科学大学的 Ikuo Morita、乌普萨拉的 E. H. Oliw 与迪肯大学的 Andrew Sinclair 在列，米兰的 Carlo Agostoni 与布莱根妇女医院的 Nan Chiang 也在名单之内。

• Manuscripts enter through Editorial Manager at submit.elsevier.com/PLEFA, the portal linked from the journal page.稿件经 Editorial Manager 进入评审流程，入口为 submit.elsevier.com/PLEFA，期刊页面直接链接至该端口。

• Published medians give 22 days from submission to first decision, 86 days to a decision after review, 97 days from submission to acceptance and 3 days from acceptance to an online version.官方公布的流程中位数有四项，投稿到首次决定 22 天，评审后决定 86 天，投稿到接收 97 天，接收到上线 3 天。

• Every paper is refereed before acceptance, and the stated preference for human evidence shapes what the desk looks for in a clinical submission.所有论文在录用前均经评审，宗旨中对人体证据的偏好也影响编辑台对临床稿件的取舍。